20 April 2021 - positive test results
The AIM-listed developer of advanced diagnostics and cancer therapies has received positive data from the clinical validation of its antigen lateral flow tests and this should lead to the commercial roll out of these tests across Europe in May. This is clearly very positive news for the company and has propelled the shared price up towards the all-time high of 275p hit last month. The shares could have further to go and remain a BUY
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
